Capital Cube • 6 months ago
Categories: Yahoo Finance Click here to see latest analysis Albioma reports financial results for the half-year ended June 30, 2016. We analyze the earnings along side the following peers of Albioma – ENGIE SA and Electricite de France SA (ENGI-FR and EDF-FR) that have also reported for this period. Highlights Year-on-year change in operating cash flow of -14.06% ... Read more (Read more...)
TheStreet.com • last year
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Insider Monkey • last year
Biotech is a hot segment right now and even though it has many opportunities, it is also associated with a lot of risks. Out of hundreds of companies, it can be difficult to pick the real winners, but one of the easy ways to find some of the best-performing picks is to look at the […]
Insider Monkey • 2 years ago
The biotechnology industry is up by more than 50% over the last year, but these towering returns don’t come without great risk and volatility. However, an investor can improve his chances of picking up a high return biotech stock if he were to follow hedge funds, taking advantage of their rigorous fundamental research. With that
Zacks • 2 years ago
ARCA biopharma's (ABIO) experimental heart failure drug, Gencaro, has been granted Fast Track status in the U.S. for the prevention of atrial fibrillation.
TheStreet.com • 2 years ago
Shares of ARCA biopharma (ABIO) soared Monday after the company announced that the Food and Drug Administration had designated as a Fast Track development program the investigation of Gencaro.
ABIO : Summary for ARCA biopharma, Inc. - Yahoo Finance
ARCA biopharma, Inc. (ABIO)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||2.10 x 1500|
|Ask||12.95 x 600|
|Day's Range||2.54 - 2.80|
|52 Week Range||2.15 - 4.35|
|PE Ratio (TTM)||-1.14|
|Earnings Date||Mar 15, 2017 - Mar 20, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||16.50|